These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 32382775

  • 1. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
    Ding X, Huang W, Peng Y, Fan H, Zhu Y, Liu X, Yang Y, Guo Q, Qiu L, Dai Y, Zou D, Jin F.
    Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
    [Abstract] [Full Text] [Related]

  • 2. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK.
    Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
    [Abstract] [Full Text] [Related]

  • 3. Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.
    Abid MB, De Mel S, Abid MA, Yap ES, Gopalakrishnan SK, Chen Y, Yuen YC, Wong HC, Lin A, Poon LM, Koh LP, Chng WJ, Tan LK.
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):174-179. PubMed ID: 29398647
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
    Skopec B, Skerget M, Zontar D, Zadnik V, Zver S.
    Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation.
    Wang X, Ren J, Liang X, He P.
    Hematology; 2021 Dec; 26(1):950-955. PubMed ID: 34904529
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
    Herbert KE, Gambell P, Link EK, Mouminoglu A, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM.
    Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
    [Abstract] [Full Text] [Related]

  • 19. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
    Malerba L, Mele A, Leopardi G, Stramigioli S, Politi P, Visani G.
    Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.